Teva Pharma UK has launched generic versions of Seroquel and Seroquel XL as Quetiapine and Quetiapine XL.Other generic versions are...
Teva Pharmaceutical Industries Ltd. and Auspex Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement under which...
The FDA has expanded the indication for Azilect (rasagiline tablets), from Teva Pharma, from monotherapy and adjunct to levodopa (LD)...
Alder BioPharmaceuticals, Inc.announced that it has entered into a European patent settlement and global license agreement with Teva Pharmaceuticals International...
Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. announced a global agreement to develop and commercialize fasinumab, Regeneron�s investigational NGF...
The FDA has approved QNASL (beclomethasone dipropionate) 40 mcg, from Teva Pharma, for the treatment of nasal symptoms associated with...
Teva Pharmaceutical announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended...
Teva Pharmaceutical Industries Ltd. announced that the FDA has approved QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler...
Teva Pharmaceutical has presented results from a post-hoc analysis of two pivotal Phase III clinical trials showing that treatment with...
Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia, a biosimilar to Lucentis® (ranibizumab ), an eye injection. The United Kingdom is the first country in Europe to authorize commercialization of Ongavia for the treatment of neovascular (wet) age-related macular degeneration (“AMD”).